Selectivity of beta-blockers, cardiovascular and all-cause mortality in people with hypoglycaemia: An observational study

Nutr Metab Cardiovasc Dis. 2019 May;29(5):481-488. doi: 10.1016/j.numecd.2019.01.006. Epub 2019 Feb 16.

Abstract

Background and aims: The association of beta-blockers and their selectivity with mortality and cardiovascular events in patients with and without hypoglycaemia is unknown.

Methods and results: Insulin-treated patients with diabetes were identified within the UK CPRD database. All-cause deaths, cardiovascular events, and hypoglycaemic episodes were captured to assess the interaction between beta-blocker therapy and selectivity with hypoglycaemia. 13,682 patients, of which 2036 (14.9%) with at least one hypoglycaemic episode, were included; 3148 deaths and 1235 cardiovascular events were recorded during a median of 2.3 and 4.7 years in patients with and without incident hypoglycaemia, respectively. Treatment with any beta-blocker was not associated with risk of death in both patients with and without hypoglycaemia, without significant interaction. Compared to no therapy, non-selective beta-blockers were associated with higher risk of death in patients without hypoglycaemia (hazard ratio (HR) 2.93 [1.26-6.83] in the fully adjusted model) but not in those with hypoglycaemia; interactions was not significant. For beta1-selective beta-blockers, there was no association with mortality in both patients with and without hypoglycaemia, without significant interaction. After missing data imputation, results were consistent for non-selective beta-blockers (HR in patients without hypoglycaemia 1.59 [1.22-2.08]) while indicated a reduced risk of death for beta1-selective beta-blockers in patients with hypoglycaemia (HR 0.76 [0.61-0.94]). Due to few cardiovascular events, complete-case analysis compared only any vs no beta-blocker therapy and indicated no associations with therapy or interaction by hypoglycaemia.

Conclusion: In patients with hypoglycaemic episodes, treatment with beta1-selective beta-blockers may potentially reduce the risk of death. These explorative findings and the potential role of confounding by indication need to be evaluated in other studies.

Keywords: Beta-blockers; Cardiovascular disease; Electronic health records; Hypoglycemia; Mortality.

Publication types

  • Comparative Study
  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists / adverse effects
  • Adrenergic beta-Antagonists / therapeutic use*
  • Aged
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / mortality
  • Cause of Death
  • Databases, Factual
  • Diabetes Mellitus / drug therapy*
  • Diabetes Mellitus / mortality
  • Female
  • Humans
  • Hypoglycemia / chemically induced
  • Hypoglycemia / mortality*
  • Hypoglycemic Agents / adverse effects*
  • Insulin / adverse effects*
  • Male
  • Middle Aged
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • Treatment Outcome
  • United Kingdom / epidemiology

Substances

  • Adrenergic beta-Antagonists
  • Hypoglycemic Agents
  • Insulin